- $86.51m
- $78.81m
- $1.88m
Annual balance sheet for Oncocyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7.82 | 36.5 | 20.4 | 9.43 | 8.64 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.203 | 1.64 | 2.01 | 0.484 | 1.61 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9.23 | 39.1 | 25.5 | 10.7 | 11.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6.52 | 8.53 | 10.9 | 5.44 | 6.32 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 55.4 | 160 | 100 | 74.9 | 35.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9 | 14.1 | 12.1 | 7.19 | 7.28 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 21.9 | 94.3 | 60.5 | 49.3 | 47.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 33.5 | 65.2 | 39.6 | 25.6 | -12.3 |
Total Liabilities & Shareholders' Equity | 55.4 | 160 | 100 | 74.9 | 35.1 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |